Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest

Bíborka Bereczky, Réka Gilly, E. Rásó, Ágnes Vágó, J. Tímár, J. Tóvári

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Use of heparin derivatives in several cancer types revealed that anticoagulant therapies have a beneficiary side effect: delay of tumor progression. Since there are no data on human melanoma, we have analyzed the effect of heparins in preclinical models. Neither unfractionated heparin (UFH), nor its low molecular weight derivative (LMWH) influenced in vitro or in vivo growth of HT168-M1 human melanoma cells. However, heparins significantly inhibited lung colony formation and liver metastasis development in the concentration range of 20-200 IU/kg, whereas recombinant hirudin was ineffective. The antimetastatic effect was due to an early (5-60 min) inhibition of tumor cell arrest in the lung microvasculature. Analysis of the molecular mechanism of the antimetastatic effect of heparins indicated a specific inhibition of tumor cell migration and matrix invasion. The presented experimental data suggest that heparins have specific antimetastatic effect in the case of human melanoma, which is independent from the coagulation cascade.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalClinical and Experimental Metastasis
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Heparin
Melanoma
Neoplasms
Cell Migration Inhibition
Hirudins
Lung
Microvessels
Anticoagulants
Molecular Weight
Neoplasm Metastasis
Liver
Growth
Therapeutics

Keywords

  • Cell migration
  • Human melanoma xenograft
  • Low molecular weight heparin (LMWH)
  • Metastasis
  • Unfractionated heparin (UFH)

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{91cd3e66424b461189e445e3089ca0d2,
title = "Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest",
abstract = "Use of heparin derivatives in several cancer types revealed that anticoagulant therapies have a beneficiary side effect: delay of tumor progression. Since there are no data on human melanoma, we have analyzed the effect of heparins in preclinical models. Neither unfractionated heparin (UFH), nor its low molecular weight derivative (LMWH) influenced in vitro or in vivo growth of HT168-M1 human melanoma cells. However, heparins significantly inhibited lung colony formation and liver metastasis development in the concentration range of 20-200 IU/kg, whereas recombinant hirudin was ineffective. The antimetastatic effect was due to an early (5-60 min) inhibition of tumor cell arrest in the lung microvasculature. Analysis of the molecular mechanism of the antimetastatic effect of heparins indicated a specific inhibition of tumor cell migration and matrix invasion. The presented experimental data suggest that heparins have specific antimetastatic effect in the case of human melanoma, which is independent from the coagulation cascade.",
keywords = "Cell migration, Human melanoma xenograft, Low molecular weight heparin (LMWH), Metastasis, Unfractionated heparin (UFH)",
author = "B{\'i}borka Bereczky and R{\'e}ka Gilly and E. R{\'a}s{\'o} and {\'A}gnes V{\'a}g{\'o} and J. T{\'i}m{\'a}r and J. T{\'o}v{\'a}ri",
year = "2005",
month = "1",
doi = "10.1007/s10585-005-3859-6",
language = "English",
volume = "22",
pages = "69--76",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest

AU - Bereczky, Bíborka

AU - Gilly, Réka

AU - Rásó, E.

AU - Vágó, Ágnes

AU - Tímár, J.

AU - Tóvári, J.

PY - 2005/1

Y1 - 2005/1

N2 - Use of heparin derivatives in several cancer types revealed that anticoagulant therapies have a beneficiary side effect: delay of tumor progression. Since there are no data on human melanoma, we have analyzed the effect of heparins in preclinical models. Neither unfractionated heparin (UFH), nor its low molecular weight derivative (LMWH) influenced in vitro or in vivo growth of HT168-M1 human melanoma cells. However, heparins significantly inhibited lung colony formation and liver metastasis development in the concentration range of 20-200 IU/kg, whereas recombinant hirudin was ineffective. The antimetastatic effect was due to an early (5-60 min) inhibition of tumor cell arrest in the lung microvasculature. Analysis of the molecular mechanism of the antimetastatic effect of heparins indicated a specific inhibition of tumor cell migration and matrix invasion. The presented experimental data suggest that heparins have specific antimetastatic effect in the case of human melanoma, which is independent from the coagulation cascade.

AB - Use of heparin derivatives in several cancer types revealed that anticoagulant therapies have a beneficiary side effect: delay of tumor progression. Since there are no data on human melanoma, we have analyzed the effect of heparins in preclinical models. Neither unfractionated heparin (UFH), nor its low molecular weight derivative (LMWH) influenced in vitro or in vivo growth of HT168-M1 human melanoma cells. However, heparins significantly inhibited lung colony formation and liver metastasis development in the concentration range of 20-200 IU/kg, whereas recombinant hirudin was ineffective. The antimetastatic effect was due to an early (5-60 min) inhibition of tumor cell arrest in the lung microvasculature. Analysis of the molecular mechanism of the antimetastatic effect of heparins indicated a specific inhibition of tumor cell migration and matrix invasion. The presented experimental data suggest that heparins have specific antimetastatic effect in the case of human melanoma, which is independent from the coagulation cascade.

KW - Cell migration

KW - Human melanoma xenograft

KW - Low molecular weight heparin (LMWH)

KW - Metastasis

KW - Unfractionated heparin (UFH)

UR - http://www.scopus.com/inward/record.url?scp=23944442968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944442968&partnerID=8YFLogxK

U2 - 10.1007/s10585-005-3859-6

DO - 10.1007/s10585-005-3859-6

M3 - Article

VL - 22

SP - 69

EP - 76

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 1

ER -